Akari Therapeutics, Plc
AKTXHealthcare|Biotechnology|US
$7.37
-0.38 (-4.90%)
DCF Value
$8.35
Cash / Share
$4.29
Clinical Trials (10)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03588026 Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | P3 | Completed | 9 | RCT, Open-label | rVA576 |
| NCT05061771 Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) | Bullous Pemphigoid | P3 | Withdrawn | — | RCT, Double-blind | nomacopan (rVA576) |
| NCT03829449 rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | Paroxysmal Nocturnal Hemoglobinuria | P3 | Terminated | 15 | Open-label | rVA576 |
| NCT04784455 Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy | Thrombotic Microangiopathies | P3 | Terminated | 10 | Open-label | nomacopan (rVA576) |
| NCT02031445 Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% | Atopic Dermatitis | P2 | Terminated | 73 | RCT, Double-blind | MRX-6 |
| NCT03427060 Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms | Paroxysmal Nocturnal Hemoglobinuria (PNH) | P2 | Completed | 1 | Open-label | Coversin |
| NCT04037891 Topical rVA576 for Treatment of Atopic Keratoconjunctivitis | Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal | P1P2 | Terminated | 12 | RCT, Double-blind | rVA576, rVA576 |
| NCT04035733 rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects | Bullous Pemphigoid (BP) | P2 | Completed | 9 | Open-label | rVA576 |
| NCT02591862 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) | Paroxysmal Nocturnal Haemoglobinuria (PNH) | P2 | Completed | 1 | Open-label | Coversin |
| NCT04453527 The CASCADE Study - Measures of Complement Activation and Inflammation in Patients With Covid-19 | Coronavirus | Completed | 72 | — | — |